The solute carrier family 2 member 4 (SLC2A4) gene, encoding for the insulin-dependent glucose transporter type 4 (GLUT4) in muscle and adipose tissue, has therapeutic potential for the treatment of insulin resistance in obesity and in specific cancer types [3,4]. This evidence concerns the gene SLC2A4 and obesity due to melanocortin 4 receptor deficiency.